Literature DB >> 26739622

Current understanding of interactions between nanoparticles and the immune system.

Marina A Dobrovolskaia1, Michael Shurin2, Anna A Shvedova3.   

Abstract

The delivery of drugs, antigens, and imaging agents benefits from using nanotechnology-based carriers. The successful translation of nanoformulations to the clinic involves thorough assessment of their safety profiles, which, among other end-points, includes evaluation of immunotoxicity. The past decade of research focusing on nanoparticle interaction with the immune system has been fruitful in terms of understanding the basics of nanoparticle immunocompatibility, developing a bioanalytical infrastructure to screen for nanoparticle-mediated immune reactions, beginning to uncover the mechanisms of nanoparticle immunotoxicity, and utilizing current knowledge about the structure-activity relationship between nanoparticles' physicochemical properties and their effects on the immune system to guide safe drug delivery. In the present review, we focus on the most prominent pieces of the nanoparticle-immune system puzzle and discuss the achievements, disappointments, and lessons learned over the past 15years of research on the immunotoxicity of engineered nanomaterials.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug delivery; Immunology; Immunotoxicity; Nanoparticles; Preclinical

Mesh:

Year:  2015        PMID: 26739622      PMCID: PMC4811709          DOI: 10.1016/j.taap.2015.12.022

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  163 in total

Review 1.  Recent developments in adjuvants for vaccines against infectious diseases.

Authors:  D T O'Hagan; M L MacKichan; M Singh
Journal:  Biomol Eng       Date:  2001-10-15

2.  Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors.

Authors:  Theodora Fifis; Anita Gamvrellis; Blessing Crimeen-Irwin; Geoffrey A Pietersz; Jie Li; Patricia L Mottram; Ian F C McKenzie; Magdalena Plebanski
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

Review 3.  Interaction of nanoparticles with immunocompetent cells: nanosafety considerations.

Authors:  Diana Boraschi; Luca Costantino; Paola Italiani
Journal:  Nanomedicine (Lond)       Date:  2012-01       Impact factor: 5.307

4.  Dendrimer-induced leukocyte procoagulant activity depends on particle size and surface charge.

Authors:  Marina A Dobrovolskaia; Anil K Patri; Timothy M Potter; Jamie C Rodriguez; Jennifer B Hall; Scott E McNeil
Journal:  Nanomedicine (Lond)       Date:  2011-09-30       Impact factor: 5.307

Review 5.  Lymphatic system: a prospective area for advanced targeting of particulate drug carriers.

Authors:  Indu Singh; Rajan Swami; Wahid Khan; Ramakrishna Sistla
Journal:  Expert Opin Drug Deliv       Date:  2013-12-19       Impact factor: 6.648

6.  Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes.

Authors:  L L Swystun; L Y Y Shin; S Beaudin; P C Liaw
Journal:  J Thromb Haemost       Date:  2009-01-24       Impact factor: 5.824

7.  The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells.

Authors:  Angeles Villanueva; Magdalena Cañete; Alejandro G Roca; Macarena Calero; Sabino Veintemillas-Verdaguer; Carlos J Serna; María del Puerto Morales; Rodolfo Miranda
Journal:  Nanotechnology       Date:  2009-02-24       Impact factor: 3.874

8.  A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjögren's syndrome.

Authors:  Mihir Shah; Maria C Edman; Srikanth R Janga; Pu Shi; Jugal Dhandhukia; Siyu Liu; Stan G Louie; Kathleen Rodgers; J Andrew Mackay; Sarah F Hamm-Alvarez
Journal:  J Control Release       Date:  2013-07-25       Impact factor: 9.776

9.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

10.  Induction of oxidative stress by Taxol® vehicle Cremophor-EL triggers production of interleukin-8 by peripheral blood mononuclear cells through the mechanism not requiring de novo synthesis of mRNA.

Authors:  Anna N Ilinskaya; Jeffrey D Clogston; Scott E McNeil; Marina A Dobrovolskaia
Journal:  Nanomedicine       Date:  2015-08-15       Impact factor: 5.307

View more
  69 in total

Review 1.  Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies.

Authors:  Frederik Soetaert; Preethi Korangath; David Serantes; Steven Fiering; Robert Ivkov
Journal:  Adv Drug Deliv Rev       Date:  2020-06-27       Impact factor: 15.470

Review 2.  In vitro microfluidic models of tumor microenvironment to screen transport of drugs and nanoparticles.

Authors:  Altug Ozcelikkale; Hye-Ran Moon; Michael Linnes; Bumsoo Han
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2017-02-14

Review 3.  Immunological effects of iron oxide nanoparticles and iron-based complex drug formulations: Therapeutic benefits, toxicity, mechanistic insights, and translational considerations.

Authors:  Ankit Shah; Marina A Dobrovolskaia
Journal:  Nanomedicine       Date:  2018-02-02       Impact factor: 5.307

4.  Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12-13 May 2017.

Authors:  Peter L Stern
Journal:  Ther Adv Vaccines       Date:  2017-07-20

5.  Hydrophobic Effect from Conjugated Chemicals or Drugs on In Vivo Biodistribution of RNA Nanoparticles.

Authors:  Daniel L Jasinski; Hongran Yin; Zhefeng Li; Peixuan Guo
Journal:  Hum Gene Ther       Date:  2017-10-12       Impact factor: 5.695

6.  Metallic Nanoparticles for Cancer Immunotherapy.

Authors:  Emily Reiser Evans; Pallavi Bugga; Vishwaratn Asthana; Rebekah Drezek
Journal:  Mater Today (Kidlington)       Date:  2017-12-14       Impact factor: 31.041

7.  The negative effect of magnetic nanoparticles with ascorbic acid on peritoneal macrophages.

Authors:  Klára Jiráková; Maksym Moskvin; Lucia Machová Urdzíková; Pavel Rössner; Fatima Elzeinová; Milada Chudíčková; Daniel Jirák; Natalia Ziolkowska; Daniel Horák; Šárka Kubinová; Pavla Jendelová
Journal:  Neurochem Res       Date:  2019-04-03       Impact factor: 3.996

Review 8.  Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications.

Authors:  Raziye Mohammadpour; Marina A Dobrovolskaia; Darwin L Cheney; Khaled F Greish; Hamidreza Ghandehari
Journal:  Adv Drug Deliv Rev       Date:  2019-07-08       Impact factor: 15.470

9.  Modulating protein amyloid aggregation with nanomaterials.

Authors:  Bo Wang; Emily H Pilkington; Yunxiang Sun; Thomas P Davis; Pu Chun Ke; Feng Ding
Journal:  Environ Sci Nano       Date:  2017-07-28

10.  The Effect of Size and Shape of RNA Nanoparticles on Biodistribution.

Authors:  Daniel L Jasinski; Hui Li; Peixuan Guo
Journal:  Mol Ther       Date:  2017-12-22       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.